Bristol-Myers Squibb Company stock price, BMY

Bristol-Myers Squibb Company stock chart:



Bristol-Myers Squibb Company close price: 55.89

Stock price forecast:

UP TO +4.53%
Target: 58.42

Total forecasts: 90
Reached: 73 (81.11%)

Total Win: 180.47 (321.67%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
90917481.32%184.223.60%954.57-9.38-0.98%174.843.48%
30311548.39%12.400.70%905.41-2.65-0.29%9.750.55%
1415320.00%4.140.47%677.59-6.91-1.02%-2.77-0.32%
7800.00%0.000.00%449.01-1.89-0.42%-1.89-0.42%

Showing 1-10 of 385 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-03-2555.8958.450000-00-00
2017-03-2455.7758.450000-00-00
2017-03-2356.3658.90000-00-00
2017-03-2255.7158.130000-00-00
2017-03-2156.4158.130000-00-00
2017-03-2056.2958.450000-00-00
2017-03-1956.2958.70000-00-00
2017-03-1856.2958.730000-00-00
2017-03-1757.3158.940000-00-00
2017-03-1657.6558.390000-00-00

Bristol-Myers Squibb Company latest news:


  • 02/21/2017 15:24:08

    Icahn buys Bristol-Myers shares, adding to activist pressure

    - Billionaire investor Carl Icahn has taken a stake in Bristol-Myers Squibb Co (BMY) and sees the drugmaker as a possible takeover target, according to a report published on Tuesday that sent the company's shares from a loss to more than 2 percent higher.

  • 02/02/2017 16:33:37

    BRIEF-Bristol-Myers Squibb receives FDA approval for Opdivo (Nivolumab)

    * Bristol-Myers Squibb receives FDA approval for Opdivo (Nivolumab) in previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer

  • 01/26/2017 05:19:21

    Bristol-Myers Squibb stock sinks 2.7% after fourth-quarter earnings miss and downbeat outlook

    Bristol-Myers Sqibb shares sunk 2.7% in pre-market trade Thursday after the company reported a fourth-quarter earnings miss and revenue beat. Earnings for the latest quarter were $894 million, or 53 cents per share. In the year-earlier period the company had a loss of $197 million, or 12 cents per share. Adjusted EPS was 63 cents, compared with the FactSet consensus of 67 cents. Revenue rose to $5.24 billion from $4.29 billion, beating the FactSet consensus of $5.12 billion. The company said global revenue growth was driven by sales for its blockbuster cancer drug Opdivo, along with drugs Eliquis, Orencia, Sprycel and Yervoy. Bristol-Myers confirmed its 2017 EPS guidance range of $2.47 to $2.67 and reduced its adjusted EPS guidance range to $2.70 to $2.90 from $2.85 to $3.05. Shares of Bristol-Myers have risen 0.5% over the last three months, compared with a 7.4% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/20/2017 14:16:39

    Merck will pay $625 million and royalties to settle Keytruda patent litigation with Bristol-Myers Squibb and Ono Pharma

    Merck & Co. Inc. will pay $625 million and royalties to Bristol-Myers Squibb Co. and Ono Pharmaceutical Co. Ltd. to settle patent litigation over Merck's cancer drug Keytruda, the companies said Friday afternoon. As part of the settlement all patent litigation will be dismissed, and the companies have granted certain patent rights to each other. Merck will pay royalties on global Keytruda sales of 6.5% between 2017 and the end of 2023 and 2.5% between 2024 and 2026, with the royalties being split 75/25 between Bristol-Myers and Ono. Merck said the $625 million payment would be recorded in its fourth-quarter and full-year 2016 results, but excluded from its non-GAAP results. In their lawsuit against Merck, Bristol-Myers and Ono, which made cancer drug Opdivo, said its Keytruda sales infringed on various of its global patents. Bristol-Myers shares slumped 2.2% over the last three months, compared with a 1.0% rise in Merck shares and a 6.1% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/20/2017 10:14:35

    Bristol-Myers shares fall on lung cancer timeline setback

    - Shares of Bristol-Myers Squibb (BMY) fell nearly 10 percent on Friday following Thursday's announcement that it would not seek accelerated approval of its immunotherapy drug combination in first-line lung cancer, further solidifying Merck & Co's (MRK) leading position in the burgeoning immuno-oncolgy field.

  • 01/19/2017 16:35:11

    BRIEF-Bristol-Myers decides not to pursue accelerated regulatory pathway for combination of Opdivo plus Yervoy

    * Bristol-Myers Squibb provides regulatory update in first-line lung cancer

  • More trends:

    Bristow Group IncBRS | Brixmor Property Group Inc.BRX | Broadridge Financial SolutionsBR | Brookdale Senior Living Inc.BKD | Brookfield Asset Management IncBAM | Brookfield Canada Office PropertiesBOXC | Brookfield DTLA Inc.DTLA^ | Brookfield Global Listed Infrastructure Income FunINF | Brookfield High Income Fund Inc.HHY | Brookfield Infrastructure Partners LPBIP |